Tag: Biocad

BIOCAD is Russia’s leading innovative biotechnology company which combines a world-class research and development center, ultra-modern pharmaceutical and biotechnology manufacturing facilities, and pre-clinical and clinical research infrastructure compliant with international standards.

BIOCAD is one of the few world’s full-cycle drug development and manufacturing companies, doing everything from new molecules discovery and genetic engineering to large-scale commercial manufacturing and marketing support. BIOCAD’s medicines are used to treat the most complex health conditions, such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

The company employs about 1000 people, 300 out of them scientists and researchers. In 2014 BIOCAD’s sales tripled and reached $200 million, while total amount of long-term international contracts exceeded half a billion US dollars. BIOCAD has subsidiaries in the US, Brazil, China, India, Singapore, and other countries.

BIOCAD has established a wide international presence – through a network of its subsidiaries and partnerships – in Belarus, Ukraine, Brazil, India, China and the United States. BIOCAD’s international strategy is to reinforce its own market leadership position in Russia while entering new markets, thus leveraging and balancing R&D, sales, procurement and logistic synergies across several continents. Every subsidiary or a partner company successfully combines R&D, market evaluation and business development activities, and provides access to talents, innovations and market opportunities of the region.

Russian Antitumor Drugs Received a Registration Certificate in Europe

Registration processes started in December 2018. During this time, a thorough examination of the drugs documentary and samples quality was carried out. According to the law, the first commercial serie...

BIOCAD Begins Developing COVID-19 Vaccine

Biocad, a pharmaceutical company based in Russia's St. Petersburg, has joined the quest for developing a vaccine against the novel coronavirus strain that triggered the COVID-19 pandemic, and will use...

What Can Russian Drug Producers Offer to the Arab World?

The Middle East and North Africa in 2020 will be the center of attention of Russian pharmaceutical companies focused on their products export development. The largest enterprises consider the region a...

BIOCAD Announced Plans to Introduce Netakimab and Prololimab to European Market

During the 30th anniversary CPhI Worldwide exhibition, BIOCAD employees held more than 60 meetings with representatives of the pharmaceutical industry in Europe, China, the Middle East, North Africa, ...

Biocad Received First EU Authorization to Conduct Prololimab’s Clinical Trials

Biocad received a clinical trial authorization for its original medicinal product in the EU. The company starts the clinical trial “DOMAJOR” in Slovakia of the drug prolgolimab in the treatment of non...

Biocad Received Clinical Trial Authorization for Original Medicinal Product in the EU

Biotechnology company Biocad received a clinical trial authorization for its original medicinal product in the EU. The company starts the clinical trial “DOMAJOR” in Slovakia of the drug prolgolimab i...

BIOCAD and Shanghai Pharma Agreed to Establish Joint Venture in China

BIOCAD and Shanghai Pharma Holding finalized the deal to establish a joint venture in China. On September the 17th, during a ceremony in Constantine’s Palace, Russian Prime Minister Dmitry Me...

First Russian Original Therapeutic Monoclonal Antibody is Registered

Biotechnology company BIOCAD registered its original interleukin-17 inhibitor (anti-IL-17) for the treatment of moderate to severe plaque psoriasis. Development and clinical studies of the new drug Ef...

Biocad intends to develop and bring to the Chinese market six drugs

Russian biotech company Biocad plans to develop and bring to the Chinese market at least six drugs in partnership with the Chinese holding Shanghai Pharmaceuticals.

BIOCAD and SPH agreed to start pharmaceutical production in China

BIOCAD and Shanghai Pharmaceuticals Holding used Eastern Economic Forum 2018 to sign a memorandum of understanding regarding the establishment of two joint ventures.

BIOCAD and Gem-Standard increase financing for projects at St Petersburg SEZ

On August 30, the Expert Council of Special Economic Zone (SEZ) 'St. Petersburg' approved the amendments for two ongoing projects of the existing SEZ residents - CJSC Biocad and Gem-Standard LLC.

BIOCAD started to set up equipment at its new manufacturing facility

The BIOCAD strategic investment project is entering the final stage of implementation - installation of equipment began in the building intended for manufacturing.

BIOCAD’s biosimilar of darbepoetin alfa will be available at the end of 2018

BIOCAD announced the completion of clinical trials for the first Russian-made biosimilar of darbepoetinalfa (BCD-066), which was designed to treat anemia related to chronic kidney disease or cancer.

Bioengineering and Biomedicine program opens under the BIOCAD’s patronage

A new Bioengineering and Biomedicine Master's program opens under the patronage of BIOCAD, a biotech company, in Saint-Petersburg State Chemical Pharmaceutical University of the Russian Ministry of Health.

Russian biosimilar of rituximab was approved for registration in Cuba

Cuban Ministry of Health (CECMED) approved for registration the biosimilar of rituximab manufactured by BIOCAD, a Russian biotech company. Supplies of this drug to Cuba are scheduled for the end of 2018.

BIOCAD will invest $26 million in infrastructure for gene therapies development

The agreements on collaboration and joint research in the area of adoptive immunotherapy were signed between V.A. Almazov National Medical Research Center and BIOCAD, a biotech company, on May 24, 2018.